Healius Ltd
HLS
Company Profile
Business description
Healius is Australia’s second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.
Contact
161 Castlereagh Street
Level 22
SydneyNSW2000
AUST: +61 294329400
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2025
Employees
10,500
Healius Ltd News & Analysis
stocks
Top-rated funds love these 3 cheap ASX shares
These companies could offer good value and, as of the latest data and have the stamp of approval from Morningstar Gold Medalist equity funds.
stocks
Undervalued ASX 200 share in net cash position after sale of business
Proceeds from the sale don’t make up for lost earnings.
stocks
A wrap of this week's ASX earnings
WiseTech, Westpac, Domino's, a2 Milk, Judo and Charter Hall were just some of the ASX companies making headlines this week.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,567.00 | 12.10 | -0.14% |
| CAC 40 | 7,216.75 | 18.30 | 0.25% |
| DAX 40 | 19,142.46 | 137.68 | 0.72% |
| Dow JONES (US) | 43,760.71 | 352.24 | 0.81% |
| FTSE 100 | 8,149.16 | 64.09 | 0.79% |
| HKSE | 19,601.11 | 103.90 | -0.53% |
| NASDAQ | 18,881.41 | 84.74 | -0.45% |
| Nikkei 225 | 38,026.17 | 326.17 | -0.85% |
| NZX 50 Index | 12,765.24 | 28.18 | 0.22% |
| S&P 500 | 5,928.71 | 11.60 | 0.20% |
| S&P/ASX 200 | 8,323.00 | 3.30 | -0.04% |
| SSE Composite Index | 3,370.40 | 2.41 | 0.07% |